相关实验视频
Updated: Jun 5, 2025

Transcranial Direct Current Stimulation for Online Gamers
Published on: November 9, 2019
博障碍的药理管理:系统审查和网络元分析
Konstantinos Ioannidis1, Cinzia Del Giovane2, Charidimos Tzagarakis3
1Department of Psychiatry, Faculty of Medicine, University of Southampton, UK and Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
纳尔梅芬和纳尔特雷显示出治疗博障碍的证据最多,尽管它们的副作用率更高. 需要进一步的研究来为个别患者量身定制这些药物.
科学领域:
- 药理治疗博障碍的药理疗法.
- 随机对照试验的网络元分析.
背景情况:
- 临床指导方针缺乏明确性关于博障碍的首选药物在有效性和耐受性方面.
- 这项研究旨在比较可用的药理治疗博障碍的药理疗法.
研究的目的:
- 通过网络元分析,比较博障碍治疗药物的疗效和耐受性.
- 为博障碍药物治疗中的临床决策提供基于证据的见解.
主要方法:
- 对博障碍药物进行双盲随机对照试验 (RCT) 的系统搜索.
- 网络元分析 (NMA) 使用标准化平均差异 (SMD) 进行疗效和赔率比 (OR) 进行耐受性.
- 使用CINeMA框架评估证据可靠性,遵守PRISMA-NMA指南.
主要成果:
- 与安慰剂相比,nalmefene和naltrexone在减少博严重性和改善生活质量方面表现出有效性.
- 纳尔梅芬和纳尔特雷因副作用而出现明显更高的断学率,表明耐受性较低.
- 奥兰沙平和托皮拉没有显示出比安慰剂更大的疗效.
结论:
- 目前,纳尔梅芬和纳尔特雷对博障碍药物治疗有最有支持的证据.
- 进一步的临床试验和个人参与者数据分析是必要的,以完善治疗策略.
- 博障碍的个性化治疗方法需要对新型化合物和现有药物的更强有力的证据.
相关概念视频
Diagnostic and Statistical Manual of Mental Disorders (DSM)
Drug Abuse and Addiction: Pharmacological Phenomena
CNS Depressants: Alcohol and Nicotine
Antidepressant Drugs: MAOIs and Other Agents
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Psychosis: Goals of Pharmacotherapy

